The historical rank and industry rank for Sol-Gel Technologies's Net Margin % or its related term are showing as below:
SLGL'
s Net Margin % Range Over the Past 10 Years
Min: -24963.57 Med: -333.94 Max: 10.3
Current: -5.67
SLGL's Net Margin % is ranked better than 67.97% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs SLGL: -5.67
Sol-Gel Technologies (NAS:SLGL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sol-Gel Technologies Net Margin % Related Terms
Sol-Gel Technologies Net Margin % Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sol-Gel Technologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (SLGL) has a Net Margin % of -3,450.93% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sol-Gel Technologies and its competitors. According to the industry distribution chart, Sol-Gel Technologies ranks #303 out of 946 companies in the Biotechnology industry, placing it in the top 32%.
Is Sol-Gel Technologies' Net Margin % too high?
Sol-Gel Technologies' current Net Margin % is -3,450.93%. Based on the distribution chart, Sol-Gel Technologies ranks #303 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sol-Gel Technologies has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Net Margin % compare to ALEC and LENZ?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #303 out of 946 companies for Net Margin %. This puts Sol-Gel Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sol-Gel Technologies and its competitors. Sol-Gel Technologies's current Net Margin % is -3,450.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.37, compared to a current price of $74.40 — trading 13.8% above its estimated fair value. The current Net Margin % is -3,450.93%. Sol-Gel Technologies' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Net Margin % is -3,450.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $74.40 is trading 13.8% above its estimated GF Value™ of $65.37.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
Net Margin %: -3,450.93%
GF Value™: $65.37 vs. price of $74.40 (13.8% above fair value)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
56GF Score
Get the complete analysis for SLGL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
